Bispecific ADCs could unlock thousands of new cancer targets

Bispecific antibody-drug conjugates (ADCs) present a novel approach in cancer therapy by targeting two different antigens, potentially increasing the number of druggable cancer targets and improving treatment specificity and efficacy.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.